Is the 3D-PANC MSP Model Superior to CT for Assessing Response to Neoadjuvant Treatment in PCA Patients?

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorFundación para la Investigación del Hospital Clínico de Valencia

About this trial

Prospective multicenter study in which all patients with borderline or locally advanced pancreatic adenocarcioma undergoing neoadjuvant chemotherapy and surgical exploration with curative intent will be included for one year. Preoperative images by traditional CT and 3D-MSP technology will be evaluated, comparing the accuracy variables (sensitivity, specificity, predictive values, area under the curve, concordance index) of both techniques with the gold standard (results of surgery and histopathological analysis).

Eligibility criteria

Qualifiers

None

Disqualifiers

Patients younger than 18 years of age.

Patients under 18 years of age.

Disease progression during neoadjuvant treatment.

No preoperative CT scan.

Trial design

Treatments tested in this trial

  • Three dimensional imaging technology (3D-PANC MSP model)
  • Computerized tomography group (conventional CT)

Treatment groups

70 Participants
are divided into 1 treatment group